User: Guest  Login
Title:

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.

Document type:
Article; Journal Article
Author(s):
Turner, Nicholas C; Laird, A Douglas; Telli, Melinda L; Rugo, Hope S; Mailliez, Audrey; Ettl, Johannes; Grischke, Eva-Maria; Mina, Lida A; Balmaña, Judith; Fasching, Peter A; Hurvitz, Sara A; Hopkins, Julia F; Albacker, Lee A; Chelliserry, Jijumon; Chen, Ying; Conte, Umberto; Wardley, Andrew M; Robson, Mark E
Abstract:
These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib in the open-label, two-cohort, Phase 2 ABRAZO trial in germline BRCA1/2-mutation carriers. In the evaluable intent-to-treat population (N = 60), 58 (97%) patients harbor ≥1 BRCA1/2 mutation(s) in tumor sequencing, with 95% (53/56) concordance between germline...     »
Journal title abbreviation:
NPJ Breast Cancer
Year:
2023
Journal volume:
9
Journal issue:
1
Fulltext / DOI:
doi:10.1038/s41523-023-00561-y
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/37803017
TUM Institution:
145; Klinik und Poliklinik für Frauenheilkunde (Prof. Kiechle)
 BibTeX